University of Pennsylvania Medical Center Guidelines for Antibiotic Use
Liposomal Amphotericin B (AmBisome®)Guidelines
|
|
|
Bone marrow transplant (BMT) and solid organ transplant (SOT) patients with baseline SCr > 2.5 mg% or est CrCl < 30 mL/min may receive LAB without a trial of CAB.
In all other patients with baseline SCr < 2.5 mg% and est CrCl < 30 mL/min, a trial of CAB should be attempted. If there is a 20% increase in SCr on CAB, the patient may be switched to LAB. (Note that the day-to-day variation of the laboratory assay for serum creatinine can be as much as 10%.)
Patients with end-stage renal disease (ESRD) on chronic peritoneal dialysis (PD) or hemodialysis (HD) will receive CAB.
Patients will be assessed weekly for improvments in renal function on LAB. Patients whose SCr has returned to baseline will receive another trial of CAB.
|
|
Patients who are converted to LAB for rigors will receive another trial of CAB after 1 week. |
|
|
|
Indication |
Dose |
Empiric therapy in febrile neutropenia |
1 mg/kg/day |
Dose increase from 1 mg/kg/day to 3 mg/kg/day
|
|
Yeasts/molds |
3 mg/kg/day |
Dose increase from 3 mg/kg/day to 5 mg/kg/day (for biopsy proven infection)
|
|
Central nervous system infections with Aspergillus sp. |
5 mg/kg/day |
Written by Ann Marie Marr 7/10/06